Lesson from pre-clinical and clinical studies of next-generation CD40 antibodies, together with mechanistic knowledge of the cellular pathways that mediate efficacy and toxicity, may enable the development of additional cell- and tumor-selective agonists with an improved therapeutic window. This evidence concerns the gene CD40 and neoplasm.